Overview: Anti-dsDNA IgG Antibody Rapid TestIntroduction: The Anti-dsDNA IgG Antibody Rapid Test is a diagnostic tool designed to detect Anti-double-stranded DNA (dsDNA) IgG antibodies in serum, whole blood, or saliva samples, facilitating the screening of systemic lupus erythematosus (SLE). These autoantibodies are highly specific for lupus, presenting with fatigue, joint pain, and severe complications like kidney failure or vasculitis if untreated, particularly in young women. Per the 2023 American College of Rheumatology guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a valuable tool for initial screening in rheumatology clinics. This rapid diagnostic falls under immunology and targets individuals with systemic symptoms or family history, addressing the challenge of early detection to guide immunosuppressive therapy like hydroxychloroquine. With morbidity rates elevated due to chronic flares, the test supports public health efforts by enabling early identification, facilitating specialist referrals, and reducing organ damage. Its multi-sample capability enhances its utility.Other Names: Anti-dsDNA IgG Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Inova Diagnostics, this test advanced lupus detection, providing a rapid alternative to ELISA.Purpose: The test screens for Anti-dsDNA IgG to guide lupus diagnosis, assess disease activity, and inform treatment and prevention strategies.Test Parameters: Presence of Anti-dsDNA IgG Antibody, detected with high specificity to indicate autoimmune activity, typically detectable in serum or blood during active lupus flares.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, joint pain, or rash.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, joint pain, rash, or prior autoimmune conditions, as well as any family history of lupus or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated lupus including kidney failure, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent infections can affect results. Correlation with ANA or kidney biopsy is recommended to confirm findings.Clinical Significance: A positive result indicates possible lupus, necessitating further investigation like kidney function tests or immunosuppressive therapy. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Rheumatologists should be consulted for case management, treatment planning, and coordination with autoimmune disease programs.Additional Supporting Tests: ANA, kidney biopsy, or Anti-dsDNA follow-up assays for confirmation.Test Limitations: The test may produce false negatives in early disease or false positives in other autoimmune conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ACR Guidelines 2023, Lupus 2024, Rheumatology 2025.